Mauro Andreotti

List of Publications by Year in descending order

97 papers	2,004 citations	257450 24 h-index	276875 41 g-index
99 all docs	99 docs citations	99 times ranked	2854 citing authors

#	Article	IF	Citations
1	IFN-Î±-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T cells against exogenous viral antigens. European Journal of Immunology, 2006, 36, 2046-2060.	2.9	132
2	Potent Immune Response against HIV-1 and Protection from Virus Challenge in hu-PBL-SCID Mice Immunized with Inactivated Virus-pulsed Dendritic Cells Generated in the Presence of IFN-Î±. Journal of Experimental Medicine, 2003, 198, 361-367.	8.5	130
3	Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. Aids, 2000, 14, 251-261.	2.2	86
4	Probiotic supplementation promotes a reduction in Tâ€cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ARTâ€treated HIVâ€1â€positive patients. Immunity, Inflammation and Disease, 2017, 5, 244-260.	2.7	84
5	Novel Bifunctional Quinolonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors:â€‰ Design, Synthesis, Biological Activities, and Mechanism of Action. Journal of Medicinal Chemistry, 2006, 49, 1939-1945.	6.4	82
6	Monocyte-Derived Dendritic Cells Generated After a Short-Term Culture with IFN-Î± and Granulocyte-Macrophage Colony-Stimulating Factor Stimulate a Potent Epstein-Barr Virus-Specific CD8+ T Cell Response. Journal of Immunology, 2003, 170, 5195-5202.	0.8	79
7	IFN-Î± promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood, 2004, 103, 980-987.	1.4	68
8	HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS. Current HIV Research, 2011, 9, 148-153.	0.5	68
9	Triple Antiretroviral Prophylaxis Administered During Pregnancy and After Delivery Significantly Reduces Breast Milk Viral Load. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 286-291.	2.1	61
10	Maternal Antiretroviral Therapy for the Prevention of Mother-To-Child Transmission of HIV in Malawi: Maternal and Infant Outcomes Two Years after Delivery. PLoS ONE, 2013, 8, e68950.	2.5	56
11	Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA. Journal of Clinical Virology, 2009, 46, 367-370.	3.1	54
12	Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. Journal of Virological Methods, 2016, 229, 35-39.	2.1	53
13	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. JAMA Network Open, 2021, 4, e2136246.	5.9	50
14	Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. Aids, 2005, 19, 1843-1847.	2.2	47
15	Novel Quinolinonyl Diketo Acid Derivatives as HIV-1 Integrase Inhibitors: Design, Synthesis, and Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 4744-4750.	6.4	45
16	Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. Journal of Clinical Virology, 2010, 47, 4-7.	3.1	45
17	Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB) Tj ETQq1 1 0.784314 rgBT /O Diseases, 2017, 65, 1878-1883.	5.8	42
18	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. Antiviral Therapy, 2012, 17, 1511-1519.	1.0	37

#	Article	IF	Citations
19	Determinants of Virologic and Immunologic Outcomes in Chronically HIV-Infected Subjects Undergoing Repeated Treatment Interruptions. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 39-47.	2.1	36
20	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology, 2015, 12, 4.	2.0	35
21	Single-nucleotide polymorphisms in human Î²-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. Aids, 2008, 22, 1515-1517.	2.2	33
22	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 1027-1030.	3.0	32
23	HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load (< 400) Tj ETQq1 1 0.784314 rgBT /Overloc	0.5	31
24	Reconstitution of Intestinal CD4 and Th17 T Cells in Antiretroviral Therapy Suppressed HIV-Infected Subjects: Implication for Residual Immune Activation from the Results of a Clinical Trial. PLoS ONE, 2014, 9, e109791.	2.5	26
25	Quality of life outcomes of combination zidovudineâ€“didanosineâ€“nevirapine and zidovudineâ€“didanosine for antiretroviral-naive advanced HIV-infected patients. Aids, 2000, 14, 2567-2574.	2.2	24
26	HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*. HIV Medicine, 2002, 3, 75-84.	2.2	22
27	Association between Cellular Human Immunodeficiency Virus DNA Level and Immunological Parameters in Patients with Undetectable Plasma Viremia Level during Highly Active Antiretroviral Therapy. Journal of Clinical Microbiology, 2005, 43, 6183-6185.	3.9	21
28	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology, 2007, 4, 17.	2.0	20
29	Interleukin-15 enhances the secretion of IFN-Î³ and CC chemokines by natural killer cells from HIV viremic and aviremic patients. Immunology Letters, 2006, 103, 192-195.	2.5	19
30	Discordant response to antiretroviral therapy. Aids, 2002, 16, 1877-1885.	2.2	18
31	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. Antimicrobial Agents and Chemotherapy, 2006, 50, 3407-3417.	3.2	18
32	Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmuL). HIV Medicine, 2004, 5, 1-10.	2.2	17
33	Quantification of HIV-RNA from dried blood spots using the Siemens VERSANT(R) HIV-1 RNA (kPCR) assay. Journal of Antimicrobial Chemotherapy, 2011, 66, 2823-2826.	3.0	15
34	Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	15
35	Development of a novel human phage display-derived anti-LAG3 scFv antibody targeting CD8+ T lymphocyte exhaustion. BMC Biotechnology, 2019, 19, 67.	3.3	15
36	Measurement of viral load by the automated Abbott real-time HIV-1 assay using dried blood spots collected and processed in Malawi and Mozambique. South African Medical Journal, 2015, 105, 1036.	0.6	14

#	Article	IF	Citations
37	Performance of Cepheid Xpert HIV-1 viral load plasma assay to accurately detect treatment failure. Aids, 2019, 33, 1881-1889.	2.2	14
38	Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment1. Antiviral Research, 2000, 47, 189-198.	4.1	13
39	Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of motherâ€toâ€infant transmission in Malawi. Journal of Medical Virology, 2012, 84, 1553-1557.	5.0	13
40	Hepatitis B virus motherâ€toâ€child transmission among <scp>HIV</scp>â€infected women receiving lamivudineâ€containing antiretroviral regimens during pregnancy and breastfeeding. Journal of Viral Hepatitis, 2015, 22, 289-296.	2.0	13
41	Hospitalizations and Costs of Treatment for Protease Inhibitor-Based Regimens in Patients with Very Advanced HIV-Infection (CD4 < 50/mm3). HIV Clinical Trials, 2000, 1, 9-16.	2.0	12
42	Vav exchange factor counteracts the HIV-1 Nef-mediated decrease of plasma membrane GM1 and NF-AT activity in T cells. European Journal of Immunology, 2003, 33, 2186-2196.	2.9	12
43	The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi. BMC Infectious Diseases, 2014, 14, 180.	2.9	12
44	Beneficial Effects of Fermented Papaya Preparation (FPPÂ®) Supplementation on Redox Balance and Aging in a Mouse Model. Antioxidants, 2020, 9, 144.	5.1	12
45	The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Medicine, 2009, 10, 477-481.	2.2	11
46	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. Archives of Virology, 2017, 162, 2565-2577.	2.1	11
47	APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz. Frontiers in Immunology, 2018, 9, 1839.	4.8	11
48	Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. Aids, 2007, 21, 2360-2362.	2.2	10
49	In vivo antiaging effects of alkaline water supplementation. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 657-664.	5.2	10
50	A Randomized Trial Comparing the Introduction of Ritonavir or Indinavir in 1251 Nucleoside-Experienced Patients with Advanced HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1809-1820.	1.1	9
51	Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. Clinical and Experimental Immunology, 2004, 135, 280-285.	2.6	9
52	Comparison of HIV Type 1 Sequences from Plasma, Cell-Free Breast Milk, and Cell-Associated Breast Milk Viral Populations in Treated and Untreated Women in Mozambique. AIDS Research and Human Retroviruses, 2009, 25, 707-711.	1.1	9
53	Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2016, 32, 737-742.	1.1	9
54	Plasma levels of CRP, neopterin and IP-10 in HIV-infected individuals with and without pulmonary tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100107.	1.3	9

#	Article	IF	Citations
55	Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi. International Journal of STD and AIDS, 2016, 27, 462-468.	1.1	8
56	Hepatitis E virus infection in HIV-infected pregnant women and their children in Malawi. Infectious Diseases, 2017, 49, 708-711.	2.8	8
57	Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. Aids, 2015, 30, 1.	2.2	8
58	UltraViolet SANitizing System for Sterilization of Ambulances Fleets and for Real-Time Monitoring of Their Sterilization Level. International Journal of Environmental Research and Public Health, 2022, 19, 331.	2.6	8
59	DC contact with HIVâ€1â€infected cells leads to high levels of Envâ€mediated virion endocytosis coupled with enhanced HIVâ€1 Ag presentation. European Journal of Immunology, 2009, 39, 404-416.	2.9	7
60	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. AIDS Research and Human Retroviruses, 2010, 26, 541-545.	1.1	7
61	CMV infection in a cohort of HIV-exposed infants born to mothers receiving antiretroviral therapy during pregnancy and breastfeeding. Medical Microbiology and Immunology, 2017, 206, 23-29.	4.8	7
62	Transcriptome Profiling of Human Monocyte-Derived Macrophages Upon CCL2 Neutralization Reveals an Association Between Activation of Innate Immune Pathways and Restriction of HIV-1 Gene Expression. Frontiers in Immunology, 2020, 11, 2129.	4.8	7
63	Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up. HIV Clinical Trials, 2007, 8, 182-188.	2.0	6
64	The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine, 2012, 57, 54-60.	3.2	6
65	Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. Infectious Diseases, 2016, 48, 317-321.	2.8	6
66	Immune Activation and Microbial Translocation Markers in HIV-Exposed Uninfected Malawian Infants in the First Year of Life. Journal of Tropical Pediatrics, 2019, 65, 617-625.	1.5	6
67	Dynamics of immunoglobulin G subclasses during the first two years of life in Malawian infants born to HIV-positive mothers. BMC Pediatrics, 2020, 20, 181.	1.7	6
68	Tumor Necrosis Factor-Î±, Interleukin-10, and Î±-Defensins in Plasma and Breast Milk of HIV-Infected Highly Active Antiretroviral Therapy-Treated and Untreated Pregnant Women in Mozambique. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 647-649.	2.1	5
69	Levels of bone markers in a population of infants exposedin uteroand during breastfeeding to tenofovir within an Option B+ programme in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 3206-3211.	3.0	5
70	Antibody response to hepatitis B vaccine in HIVâ€exposed infants in Malawi and correlation with HBV infection acquisition. Journal of Medical Virology, 2018, 90, 1172-1176.	5.0	5
71	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 68-71.	2.1	4
72	HIV-1 coreceptor switch during 2Âyears of structured treatment interruptions. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1565-1570.	2.9	4

#	Article	IF	Citations
73	Viral Sequence Analysis of HIV-Positive Women and Their Infected Children: Insight on the Timing of Infection and on the Transmission Network. AIDS Research and Human Retroviruses, 2014, 30, 1010-1015.	1.1	4
74	Recovery of Interleukin-17 Production from Interleukin-15-Stimulated CD4+ Mononuclear Cells in HIV-1-Infected Patients with Sustained Viral Suppression. Journal of Interferon and Cytokine Research, 2014, 34, 35-40.	1.2	4
75	Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. Journal of Antimicrobial Chemotherapy, 2015, 70, 2881-2884.	3.0	4
76	Soluble <scp>CD</scp>14 levels in plasma and breastmilk of Malawian <scp>HIV</scp>+ women: Lack of association with morbidity and mortality in their exposed infants. American Journal of Reproductive Immunology, 2018, 79, e12812.	1.2	4
77	IgG abnormalities in HIV-positive Malawian women initiating antiretroviral therapy during pregnancy persist after 24 months of treatment. International Journal of Infectious Diseases, 2019, 88, 1-7.	3.3	4
78	Dried blood spots for the quantitative evaluation of IgG isotypes and correlation with serum samples in HIV-exposed uninfected (HEU) infants. Journal of Immunological Methods, 2021, 493, 113019.	1.4	4
79	Cytomegalovirus (CMV) DNA load in breast milk of human immunodeficiency virus-positive women and infant CMV infection acquisition are not reduced with long-term antiretroviral therapy. Clinical Microbiology and Infection, 2017, 23, 491-492.	6.0	3
80	High CMV IgG antibody levels are associated to a lower CD4+ RESPONSE to antiretroviral therapy in HIV-infected women. Journal of Clinical Virology, 2017, 96, 17-19.	3.1	3
81	Deficit of IgG2 in HIV-positive pregnant women is responsible of inadequate IgG2 levels in their HIV-uninfected children in Malawi. Medical Microbiology and Immunology, 2018, 207, 175-182.	4.8	3
82	HIV-exposed infants with EBV infection have a reduced persistence of the immune response to the HBV vaccine. AIDS Research and Therapy, 2021, 18, 48.	1.7	3
83	Diagnostic accuracy of dried plasma spot specimens for HIV-1 viral load testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	2.1	3
84	Immunoglobulin G passive transfer from mothers to infants: total IgG, IgG subclasses and specific antipneumococcal IgG in 6-week Malawian infants exposed or unexposed to HIV. BMC Infectious Diseases, 2022, 22, 342.	2.9	3
85	Limited Risk of Drug Resistance After Discontinuation of Antiretroviral Prophylaxis for the Prevention of Breastfeeding Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 301-304.	2.1	2
86	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. AIDS Research and Human Retroviruses, 2013, 29, 1365-1369.	1.1	2
87	Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi. Journal of Antimicrobial Chemotherapy, 2014, 69, 749-752.	3.0	2
88	Isolation and preliminary characterization of a human â€˜phage displayâ€™-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. Human Antibodies, 2021, 29, 63-84.	1.5	2
89	Anti-Streptococcus pneumoniae and rotavirus IgG levels in HIV-positive women do not correlate with maternal status and infant morbidity and mortality. Journal of Medical Microbiology, 2015, 64, 795-797.	1.8	2
90	Modifications of residual viraemia in human immunodeficiency virus-1-infected subjects undergoing repeated highly active antiretroviral therapy interruptions. Journal of Medical Microbiology, 2009, 58, 121-124.	1.8	1

#	Article	IF	Citations
91	Weight Changes During and After 6 Months of Breastfeeding in HIV-Infected Mothers Receiving Antiretroviral Therapy in Malawi. AIDS Research and Human Retroviruses, 2014, 30, 1155-1157.	1.1	1
92	Seroprevalence of Brucella Infection in a Cohort of HIV-Positive Malawian Pregnant Women Living in Urban Areas. Vector-Borne and Zoonotic Diseases, 2022, , .	1.5	1
93	Targeting CCL2 inhibits viral DNA accumulation and induces APOBEC3A expression in HIV-1 infected primary human macrophages. Retrovirology, 2013, 10, .	2.0	0
94	Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi. Journal of Tropical Pediatrics, 2015, 61, 222-225.	1.5	0
95	Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e90-e91.	2.1	0
96	Low mortality rates at two years in HIV-infected individuals undergoing systematic tuberculosis testing with rapid assays at initiation of antiretroviral treatment in Mozambique. International Journal of Infectious Diseases, 2020, 99, 386-392.	3.3	0
97	Lack of new HBV infections over 2 years of follow-up in HIV-positive women receiving ART up to 6 or 24 months after delivery. Journal of Infection in Developing Countries, 2018, 12, 394-396.	1.2	0